<DOC>
	<DOCNO>NCT00414635</DOCNO>
	<brief_summary>For people HIV currently take specific medication ( include Sustiva ( efavirenz ) ) detectable viral load , study track patient take medication five day week compare seven day week .</brief_summary>
	<brief_title>FOTO : Five Consecutive Days Treatment With Efavirenz , Tenofovir , Emtricitabine Followed Two Days Off Treatment Versus Continuous Treatment</brief_title>
	<detailed_description>The purpose study evaluate virologic control weekly schedule 5 day treatment follow two day treatment versus continuous treatment regimen . This large study base result successful pilot study use protocol . The 48 week , phase IV trial address issue high cost HIV treatment , adherence problem associate daily treatment , cumulative toxicity . Virologic immunologic parameter , drug level efavirenz , adherence , toxicity measure . Subjects see CRI 6 visit randomization . Subjects randomize daily therapy cross 5/2 therapy 24 week viral load remain undetectable .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age 18 year old CD4 count &gt; = 200 Viral load &lt; 50 Treatment regimen contain efavirenz tenofovir lamivudine emtricitabine least 90 day prior screen Detectable HIV RNA ultrasensitive assay within 90 day precede screen Prior evidence intermediate high level resistance efavirenz , tenofovir cytidine analogue Hepatitis B infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>HIV/AIDS</keyword>
	<keyword>efavirenz</keyword>
	<keyword>tenofovir</keyword>
	<keyword>emtricitabine</keyword>
	<keyword>FOTO</keyword>
	<keyword>treatment interruption</keyword>
	<keyword>Atripla</keyword>
	<keyword>Truvada</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>